Ani Pharmaceuticals (ANIP) Cash from Operations (2010 - 2026)

Ani Pharmaceuticals has disclosed Cash from Operations across 17 years of filings, most recently posting 58375000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 58375000.0, up 66.83% year-over-year; the trailing twelve-month figure through Mar 2026 was 208609000.0 (up 158.37% YoY), and the FY2025 annual result was 185225000.0, up 189.34% from the prior year.
• Cash from Operations came in at 58375000.0 for Q1 2026 at Ani Pharmaceuticals, up from 30367000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 75812000.0 in Q2 2025 to a low of 18942000.0 in Q1 2022.
• The 5-year median for Cash from Operations is 20626000.0 (2023), against an average of 23257235.29.
• Across the five-year window, Cash from Operations plunged 4865.15% in 2022 and soared 1116.82% in 2023, its largest moves.
• Ani Pharmaceuticals' Cash from Operations stood at 4400000.0 in 2022, then jumped by 1116.82% to 44740000.0 in 2023, then tumbled by 64.55% to 15860000.0 in 2024, then surged by 91.47% to 30367000.0 in 2025, then surged by 92.23% to 58375000.0 in 2026.
• The last three Cash from Operations figures came in at 58375000.0 (Q1 2026), 30367000.0 (Q4 2025), and 44055000.0 (Q3 2025), per Business Quant data.